ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial
العنوان: | ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial |
---|---|
المؤلفون: | Patrice Carde, Bertrand Coiffier, Catherine Fortpied, Christophe Fermé, Guy Cantin, Matthias Karrasch, Franck Morschhauser, Anna Sureda, Bengt Glimelius, Hussein M. Khaled, Igor Aurer, Max Wolf, Serge Bologna, Isabelle Gaillard, Matthew D. Seftel, Nicolas Mounier, Pauline Brice, Pieternella J. Lugtenburg, Denis Caillot |
المصدر: | Journal of Clinical Oncology. 30:8002-8002 |
بيانات النشر: | American Society of Clinical Oncology (ASCO), 2012. |
سنة النشر: | 2012 |
مصطلحات موضوعية: | BEACOPP, Oncology, Cancer Research, medicine.medical_specialty, business.industry, medicine.medical_treatment, COPP, Surgery, Clinical trial, ABVD, Internal medicine, medicine, Overall survival, Hodgkin lymphoma, Stage (cooking), business, Time to treatment failure, medicine.drug |
الوصف: | 8002 Background: Escalated BEACOPP and derivatives achieved superior time to treatment failure (FFTF) over COPP/ABVD, resulting in higher overall survival (OS) for advanced HL. However, later clinical trials have failed to confirm OS superiority over ABVD. Methods: Eligibility criteria: clinical stage III/IV HL, International prognostic score (IPS) ≥ 3, age |
تدمد: | 1527-7755 0732-183X |
الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_________::551634cbe4f71df1ff2d1204ab3aac05Test https://doi.org/10.1200/jco.2012.30.15_suppl.8002Test |
رقم الانضمام: | edsair.doi...........551634cbe4f71df1ff2d1204ab3aac05 |
قاعدة البيانات: | OpenAIRE |
تدمد: | 15277755 0732183X |
---|